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Summary
Background: The World Health Organization target for measles elimination in the Eastern
Mediterranean Region was established in 2010. In Iran, the national measles—rubella campaign,
targeting individuals aged 5—25 years, was initiated in December 2003.
Methods: Toevaluate the impactof thecampaignafter one year, 909 serumsampleswere collected
in Shiraz, southern Iran, from a population aged 6—26 years, divided into five groups according to
age. IgG antibodies were tested using ELISA for the measles and rubella antibodies, and the plaque
reduction neutralization test (PRNT; measles) was used for samples with equivocal results.
Results: Measles protective immunity reached 80.6%, 72.7%, 84.9%, and 87.5% and rubella
immunity reached 91.0%, 99.6%, 99.6%, and 97.0% for the age groups 6—10, 11—15, 16—20,
and 20—26 years, respectively. Seropositivity to the rubella virus in this population was high,
especially in women of childbearing age (98.9%), thereby preventing congenital rubella infections.
However for measles, it was significantly lower than the rate required to achieve 95% coverage
for elimination.
Conclusions: These data indicate that an increase in immunization coverage by supplementary
administration of a second dose ofmeasles vaccine is needed to interrupt the endemic transmission
of the measles virus.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Measles is a notable cause of mortality and morbidity in
children and is responsible for 4% of the six million annual
deaths in children under five years of age. Ninety-eight
percent of these deaths occur in developing countries.1* Corresponding author. Tel.: +98 7116470205;
fax: +98 7116287071.
E-mail address: bpourabbas@yahoo.com (B. Pourabbas).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2007.03.013Although the virus is highly contagious and easily trans-
mitted, measles can be effectively prevented by attenuated
live vaccine. Prevention of measles using vaccination is still a
most important task in developing countries. Target dates for
measles elimination in three World Health Organization
(WHO) regions, the Americas, Europe, and the Eastern Med-
iterranean Region (EMR), were set for 2000, 2007, and 2010,
respectively.2
Rubella is considered a mild viral infectious disease, with
man the only known reservoir; congenital rubella syndrome
(CRS) is the only remarkable complication of the disease.Published by Elsevier Ltd. All rights reserved.
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Table 1 PRNT of measles ELISA IgG equivocal samples in
different age groups
Age group
(years)
No. No. of
equivocal
PRNT
<128
PRNT
128
6—10 222 28 24 4
11—15 260 49 24 25
16—20 259 33 14 19
21—26 168 10 8 2
Total 909 120 70 50
PRNT, plaque reduction neutralization test.WHO reports reveal that a minimum of 100 000 cases of CRS
occur annually worldwide,3 but the true incidence may be
more than double that estimate.4 Prevention of CRS is best
achieved through widespread immunization, resulting in a
high seropositivity rate in pregnant women.
In 2003, the Iranian campaign was the world’s largest
vaccination operation. Measles and rubella (MR) vaccines
(measles, Edmonston Zagreb strain; rubella, RA27/3 strain;
Serum Institute of India Ltd) were administered to more than
33 million people aged between 5 and 25 years, in less than
one month. The decline in measles incidence due to the
vaccination program and the recent campaign has been
observed in children, however cases of the disease still
emerge. This might be due to primary vaccine failure, as
well as immigration from neighboring countries with low
vaccine coverage.5 The frequency of primary vaccine failure
is variable and has been shown to be a function of age at the
time of vaccination, the number of doses, the immunogeni-
city of the strain of the virus used to manufacture the
vaccine, the geographic region, and insufficient maintenance
of the cold chain.6
Therefore, a surveillance program should now be estab-
lished to monitor the impact of vaccination. The aim of this
study was to survey the efficacy of the measles and rubella
vaccination one year after the national campaign in Shiraz,
Iran.
Materials and methods
Samples
Sera were collected over the period February 2004 to
June 2005 from 909 individuals with an age range of
6—26 years among the population of Shiraz, a city in south-
ern Iran with a population of 1.1 million (according to a
2005 estimate). The specimens belonged to 505 females
and 404 males; selection was by the random sampling
method. The cases were divided into five groups according
to their ages. Considering the current population of Shiraz,
the minimum sample size required for the current study was
calculated to be 896 with a 5% error and 90% confidence
interval.
A questionnaire was used to collect demographic informa-
tion including age, sex, previous history of measles, and
vaccination in the recent campaign.
ELISA for measles and rubella specific IgG
detection
The sera were examined using solid phase ELISA IgG kits (IBL,
Immuno-Biological Laboratories, Germany) for quantitative
determination of IgG antibodies against measles and rubella.
Testing was performed according to the manufacturer’s
instructions. ‘Non-immune’ was defined as a measles IgG
concentration of <8 U/ml and a rubella IgG concentration
of<10 IU/ml. Values between 8 and 12 U/ml for measles and
10 and 15 IU/ml for rubella were regarded as ‘equivocal’, and
values of >10 U/ml for measles and >15 IU/ml for rubella
were considered as ‘immune’. The sensitivity and specificity
of tests for measles and rubella were similar with values of
95% and 98%, respectively. The sera with equivocal antibodyvalues for measles detected by ELISAwere retested by plaque
reduction neutralization test.
Plaque reduction neutralization test (PRNT)
All sera with equivocal measles antibody values were re-
tested by the PRNT based on the standard protocol.7 Briefly,
serum samples were diluted two-fold from 1:8 to 1:256,
mixed with an equal volume of the vaccine strain virus
(Edmonston Zagreb strain) containing 20—30 PFU, and incu-
bated at 36 8C for 2.5 h. Serum/virus mixtures were trans-
ferred to 16-mm culture plates containing a vero cell
monolayer. These plates were incubated at 37 8C in a humi-
dified CO2 incubator for 1 h. The inoculums were then
removed and replaced with overlay medium. The plates were
incubated for five days at 36 8C and the plaques were
counted. The end-point for the test was the highest dilution
of serum that reduced the number of plaques by 50%. A PRNT
titer of >1:120 was considered to be a level of antibody to
provide protection against measles.8
Statistical analysis
Statistical analysis was carried out using SPSS software ver-
sion 11 (Chicago, IL, USA) using Chi-square and regression
analysis tests. A p-value of less than 0.05 was considered
significant.
Results
Nine hundred and nine samples from the five age groups were
tested by ELISA for measles and rubella. One hundred and
twenty samples with equivocal results for measles were re-
examinedwith PRNT (Table 1). No hemagglutination inhibition
test was performed for the equivocal cases of rubella, due to
the low number of cases (seven samples); for the equivocal
measles cases (120 samples) it was worthwhile performing
PRNT. In total, 735 (80.9%) sera were positive for measles IgG
and 882 (97.0%) were positive for rubella IgG (Table 2).
The measles antibody prevalence was higher in women,
although the results were not statistically significant. Due to
the recent vaccine campaign, the measles antibody preva-
lence showed no significant difference in any of the groups;
however, a difference was visible in the group aged 11—15
years. Using the regression analysis model, the seropositivity
rate was not correlated to age, which was statistically sig-
nificant ( p < 0.001).
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Table 2 Measles and rubella seroprevalance in different age groups one year after the immunization campaign in Shiraz, Iran
(2004—2005)
No. Age groups (years) No. Measles Rubella
Positive (%) Negative (%) Positive (%) Negative (%)
1 6—10 222 179 (80.6) 43 (19.4) 202 (91.0) 20 (9.0)
2 11—15 260 189 (72.7) 71 (27.3) 259 (99.6) 1 (0.4)
3 16—20 259 220 (84.9) 39 (15.1) 258 (99.6) 1 (0.4)
4 21—26 168 147 (87.5) 21 (12.5) 163 (97.0) 5 (3.0)
Total 909 735 (80.9) 174 (19.1) 882 (97.0) 27 (3.0)A higher rate of rubella seropositivity (99.6%) was
observed in the 11—15 years and 16—20 years age groups
compared to the 6—10 years age group (91%); however the
difference between groups was not statistically significant
( p > 0.05). The seropositivity rate for rubella in 262 women
of reproductive age (16—26 years) was 98.9%.
Discussion
The control of vaccine-preventable diseases, including
measles elimination, is a high priority in the Eastern Medi-
terranean Region.9 These countries must have high-quality
immunization activities, including routine and campaign
vaccinations, and they must have improved surveillance.
These are essential if the regions are to achieve measles
elimination by 2010.9
In 2003, our country conducted a nationwide campaign
targeting 5—25 year-olds with a combined measles and
rubella vaccination program, thereby vaccinating some
33.4 million people. Vaccine administration coverage of
approximately 100% was reported among individuals aged
5—25 years in Shiraz. The incidence of measles has shown a
remarkable decline in our country in recent years due to the
routine administration of live attenuated vaccines at the
ages of 1 and 6 years, as well as the recent vaccination
campaign.5
To monitor the impact of this campaign on measles
and rubella susceptibility in the target age groups, we
collected 909 serum samples in 2004—2005 from individuals
aged 6—26 years, and screened them formeasles and rubella
antibodies.
In this survey, age-related seropositive prevalence against
measles reached 80.6% (6—10 years group), 72.7% (11—15
years group), 84.9% (16—20 years group), and 87.5% (20—26
years group). In a previous study reported in Shiraz in 2001,
the measles antibody was shown to be positive in 60.8% of
cases at 6 years of age, 45% at 10 years of age, and 96.8% at 15
years of age (due to the administration of an additional
booster dose of measles vaccine at the latter age).5 Accord-
ing to these data, a significant increase in seropositive pre-
valence was observed after the catch-up campaign. However,
it was significantly lower than the rate of seroconversion
required to achieve 95% coverage for the elimination of
measles.9 This primary failure after the campaign could be
explained by influences such as the nutritional status of
children, acute diseases during vaccination, race, environ-
mental factors, sex, and immunity status of those beingvaccinated.5 Additionally, it is estimated that, worldwide,
one out of three vaccine injections is not delivered safely.10
Maintaining high population immunity can interrupt ende-
mic transmission of the measles virus,11 but accumulation of
susceptible populations represents the greatest risk to
measles elimination.12,13 It has been documented, due to
its exceedingly high infectivity, that measles has been
observed in individuals with primary, as well as secondary
vaccine failures, even when vaccination rates have exceeded
99%.14 This group of persons would be the most likely to
support viral transmission in the absence of disease.15 There-
fore, achieving andmaintaining95% seropositivity is critical
to prevent transmission of measles.16
Our data also show that the age-related seropositive
prevalence against rubella after the campaign reached
91% (6—10 years group), 99.6% (11—15 years group), 99.6%
(16—20 years group), and 97% (21—26 years group). Among
the 262 women of reproductive age (16—26 years), the
seropositivity rate was 98.9%. However, according to our
previous study in Shiraz (2001), in the absence of a rubella
vaccination program, seropositivity was 30%, 61% and 94.2%
in individuals at 6, 10 and 15 years of age, respectively
(unpublished data).
Taken together, these data indicate that the rate of
seropositivity to rubella virus in the population studied is
high, and suggest that vaccination has been successful in
Shiraz, especially in women of childbearing age, thereby
preventing congenital rubella infection.
These results show that the success rate of measles
vaccination in the national measles—rubella campaign of
2003 in Shiraz among the target population was significantly
lower than expected, while for rubella it was excellent.
Therefore, it seems that an increase in immunization cover-
age is needed, and administration of a second dose ofmeasles
vaccine would be necessary to interrupt the endemic trans-
mission of themeasles virus. Hence, an active and case-based
surveillance program, laboratory confirmation of all sus-
pected cases, the maintaining of a routine vaccination pro-
gram, and follow-up of the campaign in order to detect
populations that are susceptible to measles, are necessary
in order to effectively control measles in Iran.
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